English
简体中文
Total: £ 56.28
Published Date: 2026-04-13 | Pages: 134 | Tables: 132 | Pharma & Healthcare
The global Dry Eye Syndrome market was valued at US$ 6115 million in 2025 and is anticipated to reach US$ 8285 million by 2032, at a CAGR of 4.5% from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Dry Eye Syndrome competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry eyes. Other associated symptoms include irritation, redness, discharge, and easily fatigued eyes. Blurred vision may also occur. The symptoms can range from mild and occasional to severe and continuous. Scarring of the cornea may occur in some cases without treatment. In this report, we mainly study the drugs and eye drops for dry eye.
The Dry Eye Syndrome market is driven by the rising prevalence of dry eye conditions globally, fueled by aging populations, increased screen time, and lifestyle-related factors. The widespread use of digital devices has significantly contributed to eye strain and reduced blink rates, leading to a surge in dry eye cases, especially among younger demographics. Additionally, growing awareness of ocular health and improved diagnosis through advanced diagnostic tools have increased patient identification and treatment rates. The introduction of innovative therapies, including anti-inflammatory eye drops, tear-stimulating drugs, and device-based treatments, is also expanding the market landscape.
Despite growing demand, the Dry Eye Syndrome market faces several challenges, including underdiagnosis, variable symptoms, and limited long-term treatment efficacy. Many patients remain undiagnosed due to the overlap of symptoms with other ocular conditions and the subjective nature of the disease. Current treatments often offer only temporary relief rather than a cure, leading to poor adherence and patient dissatisfaction. Moreover, the development of new therapies is hindered by the complex pathophysiology of the condition, which involves both aqueous and evaporative components. Addressing these challenges requires improved diagnostic criteria, personalized treatment approaches, and increased investment in research and clinical trials.
Global Dry Eye Syndrome key players include Allergan, Alcon, Novartis, Santen Pharma, Johnson & Johnson, etc. Global top five manufacturers hold a share over 60%. North America is the largest market, with a share over 55%, followed by Europe and Asia-Pacific, both have a share over 35 percent. In terms of product, Anti-inflammatory Drugs is the largest segment, with a share over 50%. And in terms of application, the largest application is Hospital, followed by Retail Pharmacy.
This report delivers a comprehensive overview of the global Dry Eye Syndrome market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Dry Eye Syndrome. The Dry Eye Syndrome market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Dry Eye Syndrome market comprehensively. Regional market sizes by Type, by Distribution Channel, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Dry Eye Syndrome manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Distribution Channel, and by region.
Market Segmentation
By Company
AbbVie
Alcon
Novartis
Santen Pharma
Johnson & Johnson
Bausch & Lomb
Thea pharmaceuticals
URSAPHARM
SIMILASAN
Akorn
United Laboratories
Sun Pharmaceutical
Jianfeng Group
OmniVision Pharma
Rohto
Prestige Consumer Healthcare
LION
Kenvue (VISINE)
Segment by Type
Artificial Tears
Anti-inflammatory Drugs
Others
by Distribution Channel
Hospital
Retail Pharmacy
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Distribution Channel, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Dry Eye Syndrome manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Dry Eye Syndrome sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Distribution Channel, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Dry Eye Syndrome Market Overview
1.1 Product Definition
1.2 Dry Eye Syndrome by Type
1.2.1 Global Dry Eye Syndrome Market Value by Type: 2025 vs 2032
1.2.2 Artificial Tears
1.2.3 Anti-inflammatory Drugs
1.2.4 Others
1.3 Dry Eye Syndrome by Distribution Channel
1.3.1 Global Dry Eye Syndrome Market Value by Distribution Channel: 2025 vs 2032
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Global Dry Eye Syndrome Market Size Estimates and Forecasts
1.4.1 Global Dry Eye Syndrome Revenue 2021–2032
1.4.2 Global Dry Eye Syndrome Sales 2021–2032
1.4.3 Global Dry Eye Syndrome Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Dry Eye Syndrome Market Competition by Manufacturers
2.1 Global Dry Eye Syndrome Sales Market Share by Manufacturers (2021–2026)
2.2 Global Dry Eye Syndrome Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Dry Eye Syndrome Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Dry Eye Syndrome, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Dry Eye Syndrome, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Dry Eye Syndrome, Product Types and Applications
2.7 Global Key Manufacturers of Dry Eye Syndrome, Date of Entry into the Industry
2.8 Global Dry Eye Syndrome Market Competitive Situation and Trends
2.8.1 Global Dry Eye Syndrome Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Dry Eye Syndrome Players Market Share by Revenue
2.8.3 Global Dry Eye Syndrome Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Dry Eye Syndrome Market Scenario by Region
3.1 Global Dry Eye Syndrome Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Dry Eye Syndrome Sales by Region: 2021–2032
3.2.1 Global Dry Eye Syndrome Sales by Region: 2021–2026
3.2.2 Global Dry Eye Syndrome Sales by Region: 2027–2032
3.3 Global Dry Eye Syndrome Revenue by Region: 2021–2032
3.3.1 Global Dry Eye Syndrome Revenue by Region: 2021–2026
3.3.2 Global Dry Eye Syndrome Revenue by Region: 2027–2032
3.4 North America Dry Eye Syndrome Market Facts & Figures by Country
3.4.1 North America Dry Eye Syndrome Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Dry Eye Syndrome Sales by Country (2021–2032)
3.4.3 North America Dry Eye Syndrome Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Dry Eye Syndrome Market Facts & Figures by Country
3.5.1 Europe Dry Eye Syndrome Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Dry Eye Syndrome Sales by Country (2021–2032)
3.5.3 Europe Dry Eye Syndrome Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Dry Eye Syndrome Market Facts & Figures by Region
3.6.1 Asia Pacific Dry Eye Syndrome Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Dry Eye Syndrome Sales by Region (2021–2032)
3.6.3 Asia Pacific Dry Eye Syndrome Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Dry Eye Syndrome Market Facts & Figures by Country
3.7.1 Latin America Dry Eye Syndrome Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Dry Eye Syndrome Sales by Country (2021–2032)
3.7.3 Latin America Dry Eye Syndrome Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Dry Eye Syndrome Market Facts & Figures by Country
3.8.1 Middle East and Africa Dry Eye Syndrome Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Dry Eye Syndrome Sales by Country (2021–2032)
3.8.3 Middle East and Africa Dry Eye Syndrome Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Dry Eye Syndrome Sales by Type (2021–2032)
4.1.1 Global Dry Eye Syndrome Sales by Type (2021–2026)
4.1.2 Global Dry Eye Syndrome Sales by Type (2027–2032)
4.1.3 Global Dry Eye Syndrome Sales Market Share by Type (2021–2032)
4.2 Global Dry Eye Syndrome Revenue by Type (2021–2032)
4.2.1 Global Dry Eye Syndrome Revenue by Type (2021–2026)
4.2.2 Global Dry Eye Syndrome Revenue by Type (2027–2032)
4.2.3 Global Dry Eye Syndrome Revenue Market Share by Type (2021–2032)
4.3 Global Dry Eye Syndrome Price by Type (2021–2032)
5 Segment by Distribution Channel
5.1 Global Dry Eye Syndrome Sales by Distribution Channel (2021–2032)
5.1.1 Global Dry Eye Syndrome Sales by Distribution Channel (2021–2026)
5.1.2 Global Dry Eye Syndrome Sales by Distribution Channel (2027–2032)
5.1.3 Global Dry Eye Syndrome Sales Market Share by Distribution Channel (2021–2032)
5.2 Global Dry Eye Syndrome Revenue by Distribution Channel (2021–2032)
5.2.1 Global Dry Eye Syndrome Revenue by Distribution Channel (2021–2026)
5.2.2 Global Dry Eye Syndrome Revenue by Distribution Channel (2027–2032)
5.2.3 Global Dry Eye Syndrome Revenue Market Share by Distribution Channel (2021–2032)
5.3 Global Dry Eye Syndrome Price by Distribution Channel (2021–2032)
6 Key Companies Profiled
6.1 AbbVie
6.1.1 AbbVie Company Information
6.1.2 AbbVie Description and Business Overview
6.1.3 AbbVie Dry Eye Syndrome Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 AbbVie Dry Eye Syndrome Product Portfolio
6.1.5 AbbVie Recent Developments/Updates
6.2 Alcon
6.2.1 Alcon Company Information
6.2.2 Alcon Description and Business Overview
6.2.3 Alcon Dry Eye Syndrome Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Alcon Dry Eye Syndrome Product Portfolio
6.2.5 Alcon Recent Developments/Updates
6.3 Novartis
6.3.1 Novartis Company Information
6.3.2 Novartis Description and Business Overview
6.3.3 Novartis Dry Eye Syndrome Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Novartis Dry Eye Syndrome Product Portfolio
6.3.5 Novartis Recent Developments/Updates
6.4 Santen Pharma
6.4.1 Santen Pharma Company Information
6.4.2 Santen Pharma Description and Business Overview
6.4.3 Santen Pharma Dry Eye Syndrome Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Santen Pharma Dry Eye Syndrome Product Portfolio
6.4.5 Santen Pharma Recent Developments/Updates
6.5 Johnson & Johnson
6.5.1 Johnson & Johnson Company Information
6.5.2 Johnson & Johnson Description and Business Overview
6.5.3 Johnson & Johnson Dry Eye Syndrome Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Johnson & Johnson Dry Eye Syndrome Product Portfolio
6.5.5 Johnson & Johnson Recent Developments/Updates
6.6 Bausch & Lomb
6.6.1 Bausch & Lomb Company Information
6.6.2 Bausch & Lomb Description and Business Overview
6.6.3 Bausch & Lomb Dry Eye Syndrome Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Bausch & Lomb Dry Eye Syndrome Product Portfolio
6.6.5 Bausch & Lomb Recent Developments/Updates
6.7 Thea pharmaceuticals
6.7.1 Thea pharmaceuticals Company Information
6.7.2 Thea pharmaceuticals Description and Business Overview
6.7.3 Thea pharmaceuticals Dry Eye Syndrome Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Thea pharmaceuticals Dry Eye Syndrome Product Portfolio
6.7.5 Thea pharmaceuticals Recent Developments/Updates
6.8 URSAPHARM
6.8.1 URSAPHARM Company Information
6.8.2 URSAPHARM Description and Business Overview
6.8.3 URSAPHARM Dry Eye Syndrome Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 URSAPHARM Dry Eye Syndrome Product Portfolio
6.8.5 URSAPHARM Recent Developments/Updates
6.9 SIMILASAN
6.9.1 SIMILASAN Company Information
6.9.2 SIMILASAN Description and Business Overview
6.9.3 SIMILASAN Dry Eye Syndrome Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 SIMILASAN Dry Eye Syndrome Product Portfolio
6.9.5 SIMILASAN Recent Developments/Updates
6.10 Akorn
6.10.1 Akorn Company Information
6.10.2 Akorn Description and Business Overview
6.10.3 Akorn Dry Eye Syndrome Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Akorn Dry Eye Syndrome Product Portfolio
6.10.5 Akorn Recent Developments/Updates
6.11 United Laboratories
6.11.1 United Laboratories Company Information
6.11.2 United Laboratories Description and Business Overview
6.11.3 United Laboratories Dry Eye Syndrome Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 United Laboratories Dry Eye Syndrome Product Portfolio
6.11.5 United Laboratories Recent Developments/Updates
6.12 Sun Pharmaceutical
6.12.1 Sun Pharmaceutical Company Information
6.12.2 Sun Pharmaceutical Description and Business Overview
6.12.3 Sun Pharmaceutical Dry Eye Syndrome Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Sun Pharmaceutical Dry Eye Syndrome Product Portfolio
6.12.5 Sun Pharmaceutical Recent Developments/Updates
6.13 Jianfeng Group
6.13.1 Jianfeng Group Company Information
6.13.2 Jianfeng Group Description and Business Overview
6.13.3 Jianfeng Group Dry Eye Syndrome Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Jianfeng Group Dry Eye Syndrome Product Portfolio
6.13.5 Jianfeng Group Recent Developments/Updates
6.14 OmniVision Pharma
6.14.1 OmniVision Pharma Company Information
6.14.2 OmniVision Pharma Description and Business Overview
6.14.3 OmniVision Pharma Dry Eye Syndrome Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 OmniVision Pharma Dry Eye Syndrome Product Portfolio
6.14.5 OmniVision Pharma Recent Developments/Updates
6.15 Rohto
6.15.1 Rohto Company Information
6.15.2 Rohto Description and Business Overview
6.15.3 Rohto Dry Eye Syndrome Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Rohto Dry Eye Syndrome Product Portfolio
6.15.5 Rohto Recent Developments/Updates
6.16 Prestige Consumer Healthcare
6.16.1 Prestige Consumer Healthcare Company Information
6.16.2 Prestige Consumer Healthcare Description and Business Overview
6.16.3 Prestige Consumer Healthcare Dry Eye Syndrome Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 Prestige Consumer Healthcare Dry Eye Syndrome Product Portfolio
6.16.5 Prestige Consumer Healthcare Recent Developments/Updates
6.17 LION
6.17.1 LION Company Information
6.17.2 LION Description and Business Overview
6.17.3 LION Dry Eye Syndrome Sales, Revenue, and Gross Margin (2021–2026)
6.17.4 LION Dry Eye Syndrome Product Portfolio
6.17.5 LION Recent Developments/Updates
6.18 Kenvue (VISINE)
6.18.1 Kenvue (VISINE) Company Information
6.18.2 Kenvue (VISINE) Description and Business Overview
6.18.3 Kenvue (VISINE) Dry Eye Syndrome Sales, Revenue, and Gross Margin (2021–2026)
6.18.4 Kenvue (VISINE) Dry Eye Syndrome Product Portfolio
6.18.5 Kenvue (VISINE) Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Dry Eye Syndrome Industry Chain Analysis
7.2 Dry Eye Syndrome Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Dry Eye Syndrome Production Mode & Process Analysis
7.4 Dry Eye Syndrome Sales and Marketing
7.4.1 Dry Eye Syndrome Sales Channels
7.4.2 Dry Eye Syndrome Distributors
7.5 Dry Eye Syndrome Customer Analysis
8 Dry Eye Syndrome Market Dynamics
8.1 Dry Eye Syndrome Industry Trends
8.2 Dry Eye Syndrome Market Drivers
8.3 Dry Eye Syndrome Market Challenges
8.4 Dry Eye Syndrome Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Dry Eye Syndrome Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Dry Eye Syndrome Market Value by Distribution Channel (US$ Million), 2025 vs 2032
Table 3. Global Dry Eye Syndrome Market Competitive Situation by Manufacturers in 2025
Table 4. Global Dry Eye Syndrome Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Dry Eye Syndrome Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Dry Eye Syndrome Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Dry Eye Syndrome Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Dry Eye Syndrome Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Dry Eye Syndrome, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Dry Eye Syndrome, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Dry Eye Syndrome, Product Types and Applications
Table 12. Global Key Manufacturers of Dry Eye Syndrome, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Dry Eye Syndrome Companies by Tier (Tier 1, Tier 2, Tier 3), based on Dry Eye Syndrome Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Dry Eye Syndrome Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Dry Eye Syndrome Sales by Region (K Units), 2021–2026
Table 18. Global Dry Eye Syndrome Sales Market Share by Region (2021–2026)
Table 19. Global Dry Eye Syndrome Sales by Region (K Units), 2027–2032
Table 20. Global Dry Eye Syndrome Sales Market Share by Region (2027–2032)
Table 21. Global Dry Eye Syndrome Revenue by Region (US$ Million), 2021–2026
Table 22. Global Dry Eye Syndrome Revenue Market Share by Region (2021–2026)
Table 23. Global Dry Eye Syndrome Revenue by Region (US$ Million), 2027–2032
Table 24. Global Dry Eye Syndrome Revenue Market Share by Region (2027–2032)
Table 25. North America Dry Eye Syndrome Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Dry Eye Syndrome Sales by Country (K Units), 2021–2026
Table 27. North America Dry Eye Syndrome Sales by Country (K Units), 2027–2032
Table 28. North America Dry Eye Syndrome Revenue by Country (US$ Million), 2021–2026
Table 29. North America Dry Eye Syndrome Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Dry Eye Syndrome Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Dry Eye Syndrome Sales by Country (K Units), 2021–2026
Table 32. Europe Dry Eye Syndrome Sales by Country (K Units), 2027–2032
Table 33. Europe Dry Eye Syndrome Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Dry Eye Syndrome Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Dry Eye Syndrome Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Dry Eye Syndrome Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Dry Eye Syndrome Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Dry Eye Syndrome Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Dry Eye Syndrome Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Dry Eye Syndrome Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Dry Eye Syndrome Sales by Country (K Units), 2021–2026
Table 42. Latin America Dry Eye Syndrome Sales by Country (K Units), 2027–2032
Table 43. Latin America Dry Eye Syndrome Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Dry Eye Syndrome Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Dry Eye Syndrome Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Dry Eye Syndrome Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Dry Eye Syndrome Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Dry Eye Syndrome Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Dry Eye Syndrome Revenue by Country (US$ Million), 2027–2032
Table 50. Global Dry Eye Syndrome Sales (K Units) by Type (2021–2026)
Table 51. Global Dry Eye Syndrome Sales (K Units) by Type (2027–2032)
Table 52. Global Dry Eye Syndrome Sales Market Share by Type (2021–2026)
Table 53. Global Dry Eye Syndrome Sales Market Share by Type (2027–2032)
Table 54. Global Dry Eye Syndrome Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Dry Eye Syndrome Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Dry Eye Syndrome Revenue Market Share by Type (2021–2026)
Table 57. Global Dry Eye Syndrome Revenue Market Share by Type (2027–2032)
Table 58. Global Dry Eye Syndrome Price (US$/Unit) by Type (2021–2026)
Table 59. Global Dry Eye Syndrome Price (US$/Unit) by Type (2027–2032)
Table 60. Global Dry Eye Syndrome Sales (K Units) by Distribution Channel (2021–2026)
Table 61. Global Dry Eye Syndrome Sales (K Units) by Distribution Channel (2027–2032)
Table 62. Global Dry Eye Syndrome Sales Market Share by Distribution Channel (2021–2026)
Table 63. Global Dry Eye Syndrome Sales Market Share by Distribution Channel (2027–2032)
Table 64. Global Dry Eye Syndrome Revenue (US$ Million) by Distribution Channel (2021–2026)
Table 65. Global Dry Eye Syndrome Revenue (US$ Million) by Distribution Channel (2027–2032)
Table 66. Global Dry Eye Syndrome Revenue Market Share by Distribution Channel (2021–2026)
Table 67. Global Dry Eye Syndrome Revenue Market Share by Distribution Channel (2027–2032)
Table 68. Global Dry Eye Syndrome Price (US$/Unit) by Distribution Channel (2021–2026)
Table 69. Global Dry Eye Syndrome Price (US$/Unit) by Distribution Channel (2027–2032)
Table 70. AbbVie Company Information
Table 71. AbbVie Description and Business Overview
Table 72. AbbVie Dry Eye Syndrome Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. AbbVie Dry Eye Syndrome Product
Table 74. AbbVie Recent Developments/Updates
Table 75. Alcon Company Information
Table 76. Alcon Description and Business Overview
Table 77. Alcon Dry Eye Syndrome Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Alcon Dry Eye Syndrome Product
Table 79. Alcon Recent Developments/Updates
Table 80. Novartis Company Information
Table 81. Novartis Description and Business Overview
Table 82. Novartis Dry Eye Syndrome Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Novartis Dry Eye Syndrome Product
Table 84. Novartis Recent Developments/Updates
Table 85. Santen Pharma Company Information
Table 86. Santen Pharma Description and Business Overview
Table 87. Santen Pharma Dry Eye Syndrome Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Santen Pharma Dry Eye Syndrome Product
Table 89. Santen Pharma Recent Developments/Updates
Table 90. Johnson & Johnson Company Information
Table 91. Johnson & Johnson Description and Business Overview
Table 92. Johnson & Johnson Dry Eye Syndrome Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Johnson & Johnson Dry Eye Syndrome Product
Table 94. Johnson & Johnson Recent Developments/Updates
Table 95. Bausch & Lomb Company Information
Table 96. Bausch & Lomb Description and Business Overview
Table 97. Bausch & Lomb Dry Eye Syndrome Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Bausch & Lomb Dry Eye Syndrome Product
Table 99. Bausch & Lomb Recent Developments/Updates
Table 100. Thea pharmaceuticals Company Information
Table 101. Thea pharmaceuticals Description and Business Overview
Table 102. Thea pharmaceuticals Dry Eye Syndrome Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Thea pharmaceuticals Dry Eye Syndrome Product
Table 104. Thea pharmaceuticals Recent Developments/Updates
Table 105. URSAPHARM Company Information
Table 106. URSAPHARM Description and Business Overview
Table 107. URSAPHARM Dry Eye Syndrome Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. URSAPHARM Dry Eye Syndrome Product
Table 109. URSAPHARM Recent Developments/Updates
Table 110. SIMILASAN Company Information
Table 111. SIMILASAN Description and Business Overview
Table 112. SIMILASAN Dry Eye Syndrome Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. SIMILASAN Dry Eye Syndrome Product
Table 114. SIMILASAN Recent Developments/Updates
Table 115. Akorn Company Information
Table 116. Akorn Description and Business Overview
Table 117. Akorn Dry Eye Syndrome Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Akorn Dry Eye Syndrome Product
Table 119. Akorn Recent Developments/Updates
Table 120. United Laboratories Company Information
Table 121. United Laboratories Description and Business Overview
Table 122. United Laboratories Dry Eye Syndrome Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. United Laboratories Dry Eye Syndrome Product
Table 124. United Laboratories Recent Developments/Updates
Table 125. Sun Pharmaceutical Company Information
Table 126. Sun Pharmaceutical Description and Business Overview
Table 127. Sun Pharmaceutical Dry Eye Syndrome Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Sun Pharmaceutical Dry Eye Syndrome Product
Table 129. Sun Pharmaceutical Recent Developments/Updates
Table 130. Jianfeng Group Company Information
Table 131. Jianfeng Group Description and Business Overview
Table 132. Jianfeng Group Dry Eye Syndrome Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Jianfeng Group Dry Eye Syndrome Product
Table 134. Jianfeng Group Recent Developments/Updates
Table 135. OmniVision Pharma Company Information
Table 136. OmniVision Pharma Description and Business Overview
Table 137. OmniVision Pharma Dry Eye Syndrome Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 138. OmniVision Pharma Dry Eye Syndrome Product
Table 139. OmniVision Pharma Recent Developments/Updates
Table 140. Rohto Company Information
Table 141. Rohto Description and Business Overview
Table 142. Rohto Dry Eye Syndrome Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 143. Rohto Dry Eye Syndrome Product
Table 144. Rohto Recent Developments/Updates
Table 145. Prestige Consumer Healthcare Company Information
Table 146. Prestige Consumer Healthcare Description and Business Overview
Table 147. Prestige Consumer Healthcare Dry Eye Syndrome Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 148. Prestige Consumer Healthcare Dry Eye Syndrome Product
Table 149. Prestige Consumer Healthcare Recent Developments/Updates
Table 150. LION Company Information
Table 151. LION Description and Business Overview
Table 152. LION Dry Eye Syndrome Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 153. LION Dry Eye Syndrome Product
Table 154. LION Recent Developments/Updates
Table 155. Kenvue (VISINE) Company Information
Table 156. Kenvue (VISINE) Description and Business Overview
Table 157. Kenvue (VISINE) Dry Eye Syndrome Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 158. Kenvue (VISINE) Dry Eye Syndrome Product
Table 159. Kenvue (VISINE) Recent Developments/Updates
Table 160. Key Raw Materials Lists
Table 161. Raw Materials Key Suppliers Lists
Table 162. Dry Eye Syndrome Distributors List
Table 163. Dry Eye Syndrome Customers List
Table 164. Dry Eye Syndrome Market Trends
Table 165. Dry Eye Syndrome Market Drivers
Table 166. Dry Eye Syndrome Market Challenges
Table 167. Dry Eye Syndrome Market Restraints
Table 168. Research Programs/Design for This Report
Table 169. Key Data Information from Secondary Sources
Table 170. Key Data Information from Primary Sources
Table 171. Authors List of This Report
List of Figures
Figure 1. Product Picture of Dry Eye Syndrome
Figure 2. Global Dry Eye Syndrome Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Dry Eye Syndrome Market Share by Type: 2025 & 2032
Figure 4. Artificial Tears Product Picture
Figure 5. Anti-inflammatory Drugs Product Picture
Figure 6. Others Product Picture
Figure 7. Global Dry Eye Syndrome Market Value by Distribution Channel (US$ Million), 2021–2032
Figure 8. Global Dry Eye Syndrome Market Share by Distribution Channel: 2025 & 2032
Figure 9. Hospital
Figure 10. Retail Pharmacy
Figure 11. Others
Figure 12. Global Dry Eye Syndrome Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 13. Global Dry Eye Syndrome Market Size (US$ Million), 2021–2032
Figure 14. Global Dry Eye Syndrome Sales (K Units), 2021–2032
Figure 15. Global Dry Eye Syndrome Average Price (US$/Unit), 2021–2032
Figure 16. Dry Eye Syndrome Report Years Considered
Figure 17. Dry Eye Syndrome Sales Share by Manufacturers in 2025
Figure 18. Global Dry Eye Syndrome Revenue Share by Manufacturers in 2025
Figure 19. Top 5 and Top 10 Global Dry Eye Syndrome Players: Market Share by Revenue in Dry Eye Syndrome in 2025
Figure 20. Dry Eye Syndrome Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 21. Global Dry Eye Syndrome Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 22. North America Dry Eye Syndrome Sales Market Share by Country (2021–2032)
Figure 23. North America Dry Eye Syndrome Revenue Market Share by Country (2021–2032)
Figure 24. United States Dry Eye Syndrome Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Canada Dry Eye Syndrome Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Europe Dry Eye Syndrome Sales Market Share by Country (2021–2032)
Figure 27. Europe Dry Eye Syndrome Revenue Market Share by Country (2021–2032)
Figure 28. Germany Dry Eye Syndrome Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. France Dry Eye Syndrome Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. U.K. Dry Eye Syndrome Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Italy Dry Eye Syndrome Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Russia Dry Eye Syndrome Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Asia Pacific Dry Eye Syndrome Sales Market Share by Region (2021–2032)
Figure 34. Asia Pacific Dry Eye Syndrome Revenue Market Share by Region (2021–2032)
Figure 35. China Dry Eye Syndrome Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Japan Dry Eye Syndrome Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. South Korea Dry Eye Syndrome Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. India Dry Eye Syndrome Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Australia Dry Eye Syndrome Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. China Taiwan Dry Eye Syndrome Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Indonesia Dry Eye Syndrome Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Thailand Dry Eye Syndrome Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Malaysia Dry Eye Syndrome Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Latin America Dry Eye Syndrome Sales Market Share by Country (2021–2032)
Figure 45. Latin America Dry Eye Syndrome Revenue Market Share by Country (2021–2032)
Figure 46. Mexico Dry Eye Syndrome Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Brazil Dry Eye Syndrome Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Argentina Dry Eye Syndrome Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Middle East and Africa Dry Eye Syndrome Sales Market Share by Country (2021–2032)
Figure 50. Middle East and Africa Dry Eye Syndrome Revenue Market Share by Country (2021–2032)
Figure 51. Turkey Dry Eye Syndrome Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Saudi Arabia Dry Eye Syndrome Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. UAE Dry Eye Syndrome Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Global Sales Market Share of Dry Eye Syndrome by Type (2021–2032)
Figure 55. Global Revenue Market Share of Dry Eye Syndrome by Type (2021–2032)
Figure 56. Global Dry Eye Syndrome Price (US$/Unit) by Type (2021–2032)
Figure 57. Global Sales Market Share of Dry Eye Syndrome by Distribution Channel (2021–2032)
Figure 58. Global Revenue Market Share of Dry Eye Syndrome by Distribution Channel (2021–2032)
Figure 59. Global Dry Eye Syndrome Price (US$/Unit) by Distribution Channel (2021–2032)
Figure 60. Dry Eye Syndrome Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
